GSK

GSK
D

GSK

Arincen73/100B

GSK P/E ratio

GSK's P/E ratio is 17.44: its share price of 50.33 over its earnings per share of 2.89 over the last twelve months.

Today
17.44
Forward P/E, next 12 months
10.05
PEG ratio
1.87
Median, 5 years
13.42
Low, 5 years
3.30
High, 5 years
25.25

P/E ratio = price ÷ EPS (last 12 months) = 50.33 ÷ 2.89 = 17.44

Each day's closing price over the earnings per share of the last four quarters reported by that day (basic EPS, adjusted for splits). The P/E moves with the price every day and with the earnings at each report.

The forward P/E divides the price by the analysts' average EPS estimate for the next twelve months: the fiscal year in progress for the months left in it, the next one for the rest. For past days it uses each year's latest estimate, as the estimates of the time were not recorded (we keep a daily copy from November 2026), so the past line reads the price against the earnings expected by the time each year was reported.

Is GSK's P/E high compared with its own history?

GSK's P/E of 17.4 is near the top of its 5-year range (3.3 to 25.3, median 13.4). Analysts expect faster growth than in recent years, which can explain part of the high P/E.

Is the price fair? See the whole check

A P/E is compared with the stock's own last five years, not with other companies. Why the market pays more or less (news, rates, the sector) is not in these figures.

P/E ratio by year and by quarter

Fiscal yearPeriod endingP/E ratioForward P/EMarket capNet income
FY2027 · Estimate31 Dec 20279.99———
FY2026 · Estimate31 Dec 202610.40———
Today17.4410.0576.36B4.43B
FY202531 Dec 202513.1910.0673.72B5.59B
FY202431 Dec 202418.678.0355.09B2.95B
FY202331 Dec 20239.649.4459.04B6.13B
FY202231 Dec 202210.649.5658.48B5.49B
FY202131 Dec 202114.8410.8952.17B3.52B
FY202031 Dec 202010.5110.8953.61B5.10B
FY201931 Dec 201913.3110.8970.12B5.27B
FY201831 Dec 201814.559.8158.87B4.05B
FY201731 Dec 201723.668.0951.31B2.17B
FY201631 Dec 201657.108.0960.64B1.06B
FY201531 Dec 20156.328.7052.91B8.37B
FY201431 Dec 201418.63—52.75B2.83B
FY201331 Dec 201311.07—62.32B5.63B
FY201231 Dec 201211.07—52.51B4.74B
FY201131 Dec 201110.81—58.98B5.46B
FY201031 Dec 201027.57—51.09B1.85B
FY200931 Dec 20099.35—53.00B5.67B
FY200831 Dec 200811.24—52.95B4.71B
FY200731 Dec 20077.38—56.02B7.59B
FY200631 Dec 20067.79—60.83B7.81B
FY200531 Dec 20059.69—66.63B6.87B
FY200431 Dec 20049.83—56.58B5.76B
FY200331 Dec 20039.44—60.18B6.38B
FY200231 Dec 20029.90—54.97B5.55B
FY200131 Dec 200117.55—83.25B4.74B
FY200031 Dec 200019.20—90.79B4.73B
FY199931 Dec 199938.20—100.28B2.63B
FY199831 Dec 199844.94—120.56B2.68B
FY199731 Dec 199729.25—82.55B2.82B
FY199631 Dec 199616.67—52.21B3.13B
FY199531 Dec 199519.95—47.52B2.38B
FY199430 Jun 199536.74—38.18B1.04B
FY199330 Jun 199420.16—26.19B1.30B
FY199230 Jun 199322.67—27.36B1.21B
FY199130 Jun 199231.09—32.11B1.03B
FY199030 Jun 199135.18—31.00B881.00M
FY198930 Jun 199024.72—19.95B807.00M
FY198830 Jun 198912.01—8.26B688.00M
FY198730 Jun 198810.23—5.94B581.00M
FY198630 Jun 198719.16—9.77B510.00M
FY198530 Jun 198615.21—6.08B400.00M

Figures in GBP. A quarter's revenue, net income and dividends are those of its last four quarters. A forecast year's P/E is today's price over the analysts' EPS estimate for that year.

See also:Market cap,P/S ratio,Dividend yield,ROE (return on equity),Debt to equity,Current ratio,All ratios

Common questions about GSK's P/E ratio

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.